Aclarion (ACON) News Today $7.04 -0.01 (-0.14%) Closing price 08/28/2025 03:48 PM EasternExtended Trading$7.06 +0.02 (+0.28%) As of 08/28/2025 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ACON Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Aclarion, Inc. (ACON) - Yahoo FinanceAugust 12, 2025 | sg.finance.yahoo.comAclarion Provides Corporate Update Highlighting Scan Volume Growth and Key Upcoming CatalystsAugust 5, 2025 | globenewswire.comAclarion, Inc. Adjourns Annual Meeting to Solicit VotesJuly 30, 2025 | theglobeandmail.comAclarion, Inc. Announces Adjournment of Annual Meeting of StockholdersJuly 7, 2025 | globenewswire.comACON - Aclarion Inc Ordinary Shares Chart - MorningstarJuly 4, 2025 | morningstar.comMAclarion Enrolls First Patient In CLARITY Trial Evaluating Nociscan In Spine Surgery - NasdaqJune 27, 2025 | nasdaq.comFirst Patient Enrolled in Aclarion's Groundbreaking CLARITY TrialJune 25, 2025 | globenewswire.comAclarion to Present NOCISCAN Technology at Leading Spine Innovation ForumJune 24, 2025 | globenewswire.comAclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial SiteMay 20, 2025 | globenewswire.comAclarion Inc Ordinary SharesMay 15, 2025 | morningstar.comMAclarion Announces Texas Back Institute as New CLARITY Trial SiteMay 12, 2025 | globenewswire.comAclarion Welcomes Advocate Health as CLARITY Trial SiteMay 5, 2025 | globenewswire.comAclarion Announces Commercial Agreement with Spine Institute of LouisianaApril 29, 2025 | globenewswire.comAclarion files $150M mixed securities shelfApril 26, 2025 | markets.businessinsider.comAclarion Releases Updated Investor Presentation in Connection with Appearance at Planet MicroCap Showcase: VEGAS 2025April 23, 2025 | globenewswire.comAclarion Announces Publication of Seminal Nociscan Cost-Effectiveness AnalysisApril 21, 2025 | globenewswire.comAclarion to Present at the Planet MicroCap Showcase: VEGAS in Partnership with MicroCapClubApril 9, 2025 | globenewswire.comAclarion to Present at the Planet MicroCap Showcase: VEGAS in Partnership with MicroCapClubApril 9, 2025 | globenewswire.comAclarion ‘s Nociscan now available in Santa Monica at MICSCApril 3, 2025 | markets.businessinsider.comAclarion Announces Expansion to Santa Monica with Medical Imaging Center of Southern CaliforniaApril 2, 2025 | markets.businessinsider.comAclarion Announces Expansion to Santa Monica with Medical Imaging Center of Southern CaliforniaApril 2, 2025 | globenewswire.comAclarion provides corporate update following Q1 strategic initiativesApril 1, 2025 | markets.businessinsider.comAclarion Provides Update on Strength of Company Positioning Following Q1 Strategic InitiativesMarch 31, 2025 | globenewswire.comAclarion announces 1-for-27 reverese stock splitMarch 26, 2025 | markets.businessinsider.comAclarion Provides Shareholder UpdateMarch 13, 2025 | globenewswire.comAclarion Announces Expansion Plans with RadNet Affiliates in New York and New JerseyMarch 6, 2025 | globenewswire.comIs Aclarion's Tie-Up With Scripps Health A Lasting Catalyst? Most Retail Traders Think It's A 'Game-Changer'March 4, 2025 | msn.comAclarion announces first commercial agreement with Scripps Health in San DiegoMarch 3, 2025 | markets.businessinsider.comAclarion Announces First Commercial Agreement with Scripps HealthMarch 3, 2025 | globenewswire.comAclarion, Inc. Announces Adjournment of Special Meeting of StockholdersFebruary 28, 2025 | globenewswire.comAclarion, Inc. (ACON) to Showcase NOCISCAN’s Impact on Spine Surgery at 2025 Spine SummitFebruary 20, 2025 | msn.comAclarion to Showcase Groundbreaking NOCISCAN Technology at the 2025 Spine SummitFebruary 20, 2025 | globenewswire.comAclarion Wins Patent, Shares Eke UpFebruary 11, 2025 | baystreet.caAclarion receives U.S. patent on expanded applications of MRS data processingFebruary 11, 2025 | markets.businessinsider.comAclarion Receives US Patent to Protect Expanded Applications of Magnetic Resonance Spectroscopy (MRS) Data Processing to Identify Pain and Infection Biomarkers Throughout the BodyFebruary 11, 2025 | globenewswire.comAclarion Announces Northwestern Medicine as First CLARITY Trial SiteFebruary 6, 2025 | globenewswire.comAclarion secures funding for pivotal CLARITY trialFebruary 4, 2025 | msn.comAclarion announces CLARITY trial for Nociscan fully fundedFebruary 4, 2025 | markets.businessinsider.com1ACON : What's Going On With Aclarion Stock Tuesday?February 4, 2025 | benzinga.comAclarion Announces CLARITY Trial for Nociscan Now Fully FundedFebruary 4, 2025 | globenewswire.comNOCISCAN touted as lumbar pain diagnostic advanceFebruary 1, 2025 | msn.comAclarion to Showcase Groundbreaking NOCISCAN Technology at the Selby Spine ConferenceJanuary 31, 2025 | globenewswire.comAclarion Inc trading halted, volatility trading pauseJanuary 31, 2025 | markets.businessinsider.comAclarion announces reverse stock split effective January 29January 31, 2025 | msn.comAclarion Inc trading halted, news pendingJanuary 30, 2025 | markets.businessinsider.comAclarion Announces Closing of $14.4 Million Public Offering of Common Stock and WarrantsJanuary 17, 2025 | finance.yahoo.comEQS-News: Aclarion Announces Closing of $14.4 Million Public Offering of Common Stock and WarrantsJanuary 17, 2025 | markets.businessinsider.comAclarion Announces Pricing of $14.4 Million Public Offering of Common Stock and WarrantsJanuary 15, 2025 | finance.yahoo.comEQS-News: Aclarion Announces Pricing of Registered Direct Offering of Common Stock Priced at the MarketJanuary 4, 2025 | markets.businessinsider.comMaxim Group Downgrades Aclarion (ACON)December 14, 2024 | msn.com Get Aclarion News Delivered to You Automatically Sign up to receive the latest news and ratings for ACON and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACON Media Mentions By Week ACON Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACON News Sentiment▼1.881.03▲Average Medical News Sentiment ACON News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACON Articles This Week▼11▲ACON Articles Average Week Get the Latest News and Ratings for ACON and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Aclarion and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Biorestorative Therapies News Today BioNexus Gene Lab News Today SunLink Health Systems News Today ATI Physical Therapy News Today NewGenIvf Group News Today Ontrak News Today IMAC News Today Aclarion News Today American Oncology Network News Today Fresenius Medical Care AG & Co. KGaA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACON) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclarion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclarion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access